Papers/PMID:33568522
Nicotinamide for the treatment of heart failure with preserved ejection fraction.
Science translational medicine2021The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
nicotinamide — decreases body weight gain over a feeding or growth period
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“However, NAM conspicuously reduced body weight gain and visceral fat accumulation without affecting lean body mass (fig. S4A), indicating improved body composition.”
Quoted verbatim from Nicotinamide for the treatment of heart failure with preserved ejection fraction.. - Study
- animal · not in humans
- Dose
- 40 mM in the drinking water
- Population
- ZSF1 obese rats (hyperphagic, leptin receptor-deficient), male and female; NAM 40 mM in drinking water
Nicotinamide for the treatment of heart failure with preserved ejection fraction.2021PMID:33568522Permalink
nicotinamide — decreases mitral E/e' ratio
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding“Importantly, NAM reduced the echocardiography-derived E/e’ ratio, a non-invasive measure of left ventricular (LV) diastolic dysfunction, to values comparable to those observed in leptin receptor-sufficient lean rats.”
Quoted verbatim from Nicotinamide for the treatment of heart failure with preserved ejection fraction.. - Study
- animal · not in humans
- Dose
- 40 mM in the drinking water
- Population
- ZSF1 obese rats (model of metabolic syndrome and HFpEF), male and female; NAM 40 mM in drinking water
Nicotinamide for the treatment of heart failure with preserved ejection fraction.2021PMID:33568522Permalink